Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/8904_2016_8 http://scihub22266oqcxt.onion/10.1007/8904_2016_8 C5509557!5509557 !27557812     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27557812 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       JIMD+Rep 2017 ; 34 (ä): 63-70 Nephropedia Template TP {{tp|p=27557812 |t=2017. Delayed Infusion Reactions to Enzyme Replacement Therapies |pdf=|usr=}}{{27557812 }} gab.com Text Delayed Infusion Reactions to Enzyme Replacement Therapies JO: JIMD Rep http://www.kidney.de/pget.php?&tw=1&pmid=27557812 #FOAvip BACKGROUND: There are currently ten intravenous enzyme replacement therapy (ERT) products available for the treatment of eight different lysosomal diseases (LD) in the USA. Additional ERT products are in clinical trials. The most common ERT adverse events are infusion reactions (IR). While IR are often defined as hypersensitivity or anaphylactoid reactions occurring concurrently with (i.e., during) infusion administration (CIR), there exists the potential for delayed infusion reactions (DIR), which present after completion of infusion administration. HYPOTHESIS: Concurrent infusion reactions (CIR) are not the only infusion reactions associated with enzyme therapy. METHODS: This study evaluated the occurrence of infusion reactions in 46 patients with LD who had received ERT for a minimum of 2 years. Infusion reactions were evaluated according to symptoms, time of onset, and duration of reactions. The frequency of infusion reactions with each ERT product was compared to that reported in the FDA-approved product package insert. RESULTS AND CONCLUSIONS: In this study, DIR were observed and occurred as often as CIR in the study population, despite not being characterized or reported in most ERT product package inserts. Effective methods for managing DIR and CIR differed, thus emphasizing the importance of monitoring for both types of infusion reactions in order to optimize outcomes for patients using ERT. Twit Text FOAVip Delayed Infusion Reactions to Enzyme Replacement Therapies ????JIMD Rep http://www.kidney.de/pget.php?&tw=1&pmid=27557812 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27557812 #FOAvip English Wikipedia <ref>{{Cite pmid|27557812 }}</ref> Delayed Infusion Reactions to Enzyme Replacement Therapies #MMPMID27557812 Karimian Z ; Whitley CB ; Rudser KD ; Utz JRJ JIMD Rep 2017[]; 34 (ä): 63-70 PMID27557812 show ga BACKGROUND: There are currently ten intravenous enzyme replacement therapy (ERT) products available for the treatment of eight different lysosomal diseases (LD) in the USA. Additional ERT products are in clinical trials. The most common ERT adverse events are infusion reactions (IR). While IR are often defined as hypersensitivity or anaphylactoid reactions occurring concurrently with (i.e., during) infusion administration (CIR), there exists the potential for delayed infusion reactions (DIR), which present after completion of infusion administration. HYPOTHESIS: Concurrent infusion reactions (CIR) are not the only infusion reactions associated with enzyme therapy. METHODS: This study evaluated the occurrence of infusion reactions in 46 patients with LD who had received ERT for a minimum of 2 years. Infusion reactions were evaluated according to symptoms, time of onset, and duration of reactions. The frequency of infusion reactions with each ERT product was compared to that reported in the FDA-approved product package insert. RESULTS AND CONCLUSIONS: In this study, DIR were observed and occurred as often as CIR in the study population, despite not being characterized or reported in most ERT product package inserts. Effective methods for managing DIR and CIR differed, thus emphasizing the importance of monitoring for both types of infusion reactions in order to optimize outcomes for patients using ERT. äDelayed Infusion Reactions to Enzyme Replacement Therapies (epmc).pdf DeepDyve Pubget Overpricing